• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Sinovac Receives RMB 20 Million Purchase Order for Healive From China's Ministry of Health to Vaccinate Earthquake Victims

Posted on: Tuesday, 27 May 2008, 12:00 CDT

BEIJING, May 27 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. , a leading provider of vaccines in China, today announced that the Ministry of Health has purchased approximately RMB 20 million (US$2.86 million) of the Company's inactivated hepatitis A vaccine, Healive(R), to vaccinate people living in the disaster zone following the May 12th earthquake. Sinovac has delivered shipments of the Healive vaccine to Sichuan, Shanxi and Gansu provinces.

Mr. Weidong Yin, Chairman, President and CEO, stated, "Sinovac is proud to provide assistance and vaccines for disease control to China after the earthquake. Infectious disease prevention is particularly important at this time in the disaster zone given that the infrastructure to deliver clean water was destroyed. Sinovac is well positioned to provide support by delivering vaccines and expertise to the disaster zone."

Immediately after the May 12th earthquake, Sinovac donated 50,000 doses of Healive and a total of RMB 610,000 to Ministry of Health of China to support disease control efforts.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com/ . To be added to our distribution list, please email: info@sinovac.com.

For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Phone: +86-10-82890088 Ext. 871 Fax: +86-10-62966910 Email: info@sinovac.com Investors/Media: Stephanie Carrington/Janine McCargo The Ruth Group Phone: +1-646-536-7017/7033 Email: scarrington@theruthgroup.com Email: jmccargo@theruthgroup.com

Sinovac Biotech Ltd.

CONTACT: Helen G. Yang of Sinovac Biotech Ltd. at +86-10-8289-0088 x871,or fax +86-10-62966910, or info@sinovac.com; investors and media shouldcontact Stephanie Carrington or Janine McCargo of The Ruth Group at The RuthGroup +1-646-536-7017 or -7033, or scarrington@theruthgroup.com orjmccargo@theruthgroup.com

Web Site: http://www.sinovac.com/

Source: PRNewswire

More News in this Category